Back
35· Cooling
Technology3h 10m ago
RAG-17 siRNA therapy demonstrated 69% SOD1 knockdown in a first-in-human ALS trial.
Archive Window: 7 Days Left
Not specified
Who
RAG-17
What
RAG-17 siRNA therapy demonstrated 69% SOD1 knockdown in a first-in-human ALS trial.
When
Thu, 16 Jul 2026 16:23:51 GMT · 3h 10m ago
Where
Not specified ·
Why
To test the efficacy of RAG-17 siRNA therapy in reducing SOD1 levels in ALS patients.
The Frontline Impact
How this affects you
The trial results suggest a potential advancement in gene silencing therapies for ALS, reshaping expectations for the durability of gene silencing.
Story chain
1 event in this threadNo related history yet - this is the origin event.